Medical Equipment and Supplies Manufacturing (U.S.) — Industry Rollup Primer

NAICS 2022 code 33911. A Histometrics rollup primer synthesizing the five child industries, for public-market and private investors.

1. Overview

This is the factory floor of medicine: the industry that makes the physical, non-electronic goods clinicians use on and inside patients — surgical instruments, catheters, needles and syringes; orthopedic and spinal implants, wound dressings, prosthetics and braces; dental chairs, implants and clear aligners; eyeglass lenses and contact lenses; and the custom crowns and dentures a dental lab fabricates one mouth at a time. If a doctor, surgeon, dentist, or optometrist holds it, implants it, or hands it to you, it was very likely built by a firm in this five-digit code.[1]

Deliberately excluded — and this matters, because it is where the largest "medtech" dollars sit — are the electronic and imaging machines: pacemakers, defibrillators, patient monitors, MRI, CT and ultrasound live in 334510 Electromedical Apparatus and 334517 Irradiation Apparatus, separate codes entirely.[1][2] So 33911 is the mechanical, material, and single-use half of the device economy, not the electronics half.

A boundary quirk worth knowing at this level. Several products that look like they belong to one child are classified in another inside the same level: intraocular lenses — the implants placed in the eye during cataract surgery — sit in 339113, not in ophthalmic goods, and ophthalmic surgical instruments and lasers sit in 339112.[5] The practical consequence is that the rollup captures far more of the eye-care manufacturing chain than the ophthalmic child alone implies; only retail optical shops, in-store lens grinding, and optometry fall outside it.[5] The same logic runs the other way in dentistry: making a zirconia blank is 339114, but milling a specific patient's crown from it is 339116.[4][6]

Why an investor cares: the whole level rides two durable, non-cyclical tailwinds — an aging population and rising chronic disease — and much of it earns money the way investors like, through recurring consumables sold again and again against an installed base (the "razor-and-blades" model that recurs in every child industry).[2][3][5] But the level is not one business. It is five very different industries fused by a shared regulator (the U.S. Food and Drug Administration) and shared buyers (hospitals, dentists, optical chains). Two of the five children are large, capital-rich, publicly investable device sectors; the other three are small, and one of them is a fragmented craft trade being slowly disintermediated. The distinctive job of this primer is to show how they differ — in size, direction, concentration, who owns them, and how you can invest — before treating the level as a whole.

2. What's inside — the five child industries and how they differ

The level splits into two heavyweights (surgical instruments and surgical appliances/implants together are ~81% of receipts) and three lightweights (dental equipment, ophthalmic goods, dental labs, ~6–7% each). But receipts share is only the start; the children diverge sharply on labor intensity, concentration, ownership, and growth direction.

Contrast table — the five children of NAICS 33911

Four contrasts do the analytical work:

• Labor intensity splits the level in two. Revenue per worker runs roughly $280K–$400K in the four manufacturing children but only ~$150K in dental labs — because a dental lab is a made-to-order craft shop where skilled hands, not automated plants, are the constraint.[6] Dental labs are ~6.5% of receipts but ~14% of the level's jobs.
• Pay follows the same split, and the gap is wide. The level averages ~$83,500 per employee.[1] Surgical instruments pays ~$93,000 — cleanroom, quality-controlled precision work.[2] The mean U.S. dental-laboratory technician earned about $52,400 in May 2024 (median $48,310).[6] The same NAICS level contains both a validated-cleanroom workforce and a low-wage craft trade.
• Fragmentation is wildly uneven. Dental labs are 58% of all firms in the level (4,669 of ~7,900) yet only ~6.5% of receipts — average revenue about $1.4M per firm and fewer than nine employees per establishment.[1][6] By contrast the average surgical-instrument establishment employs about 101 people, and ophthalmic goods manages ~$6.5B of receipts from just 280 firms.[2][5] So the level's firm count is dominated by its smallest child while its output is not.
• Direction of travel is not uniform, and even the growers do not grow smoothly. Four children have a rising long-run demand curve; one — dental labs — is structurally threatened from two sides at once, as dentists print crowns chairside and offshore labs undercut domestic pricing.[6] But the revised children also show that recent measured output has been bumpy: surgical appliances' real sectoral output fell ~8.2% from 2022 to 2023 on post-pandemic PPE normalization,[3] and U.S. optical product volumes and eye exams declined in 2025 even as higher prices lifted market value.[5] A rollup that treated all five as smoothly compounding "medtech" would miss both facts.

3. How big it is (this level's rollup figures)

Federal ground-truth for the whole of NAICS 33911:

At ~$97 billion in domestic factory shipments, 33911 is a large manufacturing sector, and its ~$83,500 average pay sits well above the U.S. manufacturing average — this is skilled, cleanroom, quality-controlled work, not commodity assembly.[1] The children's establishment counts and payroll figures reconcile to the level essentially to the dollar-rounding; their firm counts sum a little higher than the level's 7,941, which is what you expect when a company operating plants in two children is counted once in each.[1][2][3][4][5][6]

Concentration looks deceptively low — and the ladder shows why. The level's HHI of 164 and CR4 of 19.3% would read as almost perfectly competitive.[1] But that is an artifact of bundling five unrelated industries together: no company competes across all five, so no firm's share piles up at the 33911 level. Every child is more concentrated than the parent:

Two readings follow. First, concentration runs roughly inversely to size: the two children that carry ~81% of the level's receipts are among the least concentrated, while ophthalmic goods — one of the smallest — is by far the most concentrated, with the top four firms holding 59.3% and the top eight 73.3%.[5] Dental labs is the exception that is small and atomized: it takes 50 firms to reach even half of that child's revenue.[6] Second, all six of these readings sit below the 1,500 threshold antitrust agencies treat as "moderately concentrated," yet inside any single niche the reality is an oligopoly (Section 8). Read the level's low HHI as "five separate contests," not "easy entry."

The undercount caveat — read before comparing to company revenues. The $96.83B is domestic factory shipments by establishments primarily in these codes [1]. It is not what Americans spend on this equipment, for three reasons that apply across the level:

1. Imports. A large share of devices, frames, dental restorations, and components sold in the U.S. is manufactured abroad and does not appear in domestic shipments — one estimate puts ~14% of U.S.-marketed medical devices as made in China, roughly three-quarters of personal protective equipment as imported, and China as the single largest source of eyewear.[3][5]
2. Diversified giants straddle codes. The household medtech names book revenue across instruments (339112), implants (339113), the excluded electromedical codes, and overseas — so their sales are spread across, and beyond, this level. You cannot add up the companies in Section 4 to reach $97B. Even a "dental" leader is global: Align, Dentsply Sirona and Envista together report worldwide revenue larger than the entire $5.8B domestic dental-equipment child.[4]
3. Small/individual ownership is under-captured — sharpest in dental labs. Where the industry is thousands of tiny private shops (dental labs, custom optical and specialty-lens labs, small instrument machine shops), a meaningful slice of economic activity is offshored or performed in-house by dentists and optical retailers and lands in other codes entirely — a restoration milled inside a dentist's office is counted under offices of dentists, not here.[6] The dental-lab figure in particular should be read as a floor on that trade's true footprint, and private "market size" estimates for it range from about $2.4B to nearly $8B depending on what they bundle in.[6]

For scale: the broader U.S. medical-device market is estimated near $191 billion (2025), with the United States accounting for roughly 46% of global medical-device sales in 2024;[2] The Vision Council valued the 2025 U.S. optical ecosystem — exams, retail, contacts, lenses, frames, readers and sunglasses — at $69.5 billion;[5] and U.S. dental services spending was $189.2 billion in 2024, up 6.6%, of which private insurance and out-of-pocket payments funded 80%.[4][6] All are far larger than this level's $97B of domestic manufacturing, which is a clean read on making the goods, not on the end-markets that consume them.

4. The investable universe — where value concentrates across the children

The single most useful fact for an investor is that public-market access is extremely uneven across the five children. Listed opportunity clusters in the two big manufacturing children; the three small children are either dominated by foreign/diversified companies or barely listed at all.

• Where the listed money is (339112 instruments + 339113 implants, ~81% of the level). This is where the large-cap medtech names live. Diversified giants — Medtronic (MDT), Johnson & Johnson MedTech (JNJ), Stryker (SYK), Becton Dickinson (BDX), Boston Scientific (BSX), Abbott (ABT), Baxter (BAX) — book revenue across both children (plus the excluded electromedical codes).[2][3] The cleaner instrument-side plays include Intuitive Surgical (ISRG, robotic surgery), Teleflex (TFX), ICU Medical (ICUI), Merit Medical (MMSI), Integra LifeSciences (IART) and CONMED (CNMD), with listed contract manufacturer Integer Holdings (ITGR) and small-cap Utah Medical (UTMD) at the edges.[2] The cleaner implant-side plays include Zimmer Biomet (ZBH, the closest large orthopedic pure-play), Globus Medical (GMED), Enovis (ENOV), Orthofix (OFIX), Alphatec (ATEC), Smith+Nephew (SNN), and wound/ostomy specialists Solventum (SOLV), ConvaTec (CTEC.L) and Coloplast (COLO-B).[3] Broad medical-device ETFs — the iShares U.S. Medical Devices ETF (IHI, 0.38% expense ratio) and the SPDR S&P Health Care Equipment ETF (XHE, 0.35%) — bundle these together (alongside the excluded electromedical names), so they are a "medtech" bet, not a pure 33911 bet.[2]
• New since the last pass: Medline (MDLN). Medline Industries completed its IPO in December 2025, giving public investors their first direct access to the largest U.S. medical-surgical consumables platform — $28.4B of 2025 net sales, of which $13.7B is Medline-branded product.[3] It is the broadest listed exposure to hospital consumables and private-label conversion, but roughly half its sales are distribution rather than own-brand manufacturing, and its consolidated gross margin of 26.4% is a different animal from a branded implant maker's.[3]
• Dental equipment (339114) — a short listed bench. Just three mid-to-large caps offer near-pure exposure: Align Technology (ALGN, ~$4.0B 2025 revenue, 67% gross margin), Dentsply Sirona (XRAY, ~$3.68B, broad-line, mid-turnaround), and Envista (NVST, ~$2.72B, implants + orthodontics), plus diversified Solventum (SOLV, Dental Solutions ~$1.35B) and Swiss-listed Straumann (STMN / SAUHY, ~CHF 2.6B).[4] Income is scarce here — Align pays no dividend and Dentsply eliminated its dividend to cut debt.[4]
• Ophthalmic goods (339115) — no U.S. pure play, and no dedicated ETF. The closest listed proxy is The Cooper Companies (COO, CooperVision contact lenses ~$2.74B of ~$4.1B FY2025 revenue); otherwise exposure comes through diversified Bausch + Lomb (BLCO) and Alcon (ALC) — whose largest arms are surgical and intraocular-lens businesses that, at this level, land in 339113 rather than in ophthalmic goods — or foreign-listed EssilorLuxottica (ESLOY / EL, ~€28.5B 2025 revenue), the vertically integrated lens-frame-retail colossus.[5] Retail-end proxies (Warby Parker, National Vision) are optical retailers, not manufacturers, and there is no dedicated U.S. eyewear ETF — broad exposure comes bundled inside health-care funds.[5]
• Dental labs (339116) — essentially no listed play. The most fragmented child is the least investable publicly: there is no scaled U.S.-listed dental lab. Public exposure is indirect — you own the picks-and-shovels, which are largely the 339114 companies (Dentsply Sirona, Envista, Align, Straumann, Henry Schein) plus dental-3D-printing names (3D Systems, Stratasys) — or the one Hong Kong-listed operator, Modern Dental Group (SEHK: 3600, HK$3.36B group revenue in 2024, ~US$430M, of which HK$752M North American).[6]

Where private capital concentrates — the mirror image. The private/PE opportunity is inversely distributed: it is thickest exactly where public access is thinnest.

• Contract manufacturing (CDMOs) feeding 339112/339113 — a global market estimated near $89 billion in 2025 and growing double-digits, and described by one of its own listed participants as traditionally fragmented among several hundred companies — is an active PE roll-up target; large private names include Cook Medical, Freudenberg Medical and Viant.[2]
• Orthopedic, spine, and prosthetics/orthotics providers (339113) are classic PE platforms — H.I.G. Capital bought ZimVie's spine unit for $375 million in 2024; Patient Square owns Hanger. Large private manufacturers include Mölnlycke, Hollister, Ottobock and Drive DeVilbiss.[3]
• Dental (339114/339116) is arguably more PE-exposed through the customer base than the factories: Dental Service Organization (DSO) roll-ups, distributor take-privates (Patterson → Patient Square, closed April 2025), and manufacturer buyouts (ZimVie → ArchiMed).[4] Dental labs (339116) are the textbook fragmented roll-up — thousands of aging-owner independents, assembled by platforms like Cerberus-backed National Dentex, which now spans more than 55 laboratories, alongside family-owned mega-lab Glidewell.[6]
• Optical (339115) offers PE roll-ups of specialty-lens, rigid-gas-permeable and frame labs, plus foundation/nonprofit owners — Carl Zeiss is wholly owned by the Carl Zeiss Foundation and VSP Vision is a not-for-profit that owns frames, stores and an insurance plan.[5]

Net: public investors get the two big children; private investors get disproportionate access to the three small ones.

5. How the money works

Despite five different products, the level shares one dominant profit engine and one dominant constraint.

• Razor-and-blades / recurring consumables — the shared model. Across every child, the best economics come from pairing a durable good with a repeat-purchase stream, and the revised children quantify it: Intuitive Surgical's instruments, accessories, service and leases generated $8.5B of its $10.1B 2025 revenue — 84% recurring;[2] more than two-thirds of Stryker's U.S. knee procedures ran on its MAKO robots by end-2025, locking in implant pull-through;[3] consumables, service and spare parts are about 70% of Envista's Equipment & Consumables segment;[4] and a contact-lens wearer re-orders daily disposables for decades.[5] Recurring revenue against a growing installed base is the metric to watch in four of the five children.
• High gross margins — but the spread across the level is wider than "branded medtech" suggests. Branded makers cluster in the 50–67% range (Align 67%, Stryker 64%, Envista 55%, Dentsply Sirona 50%), protected by patents, FDA clearance, and clinician switching costs.[2][3][4] The consumable, distribution and contract tiers are a different business entirely: ICU Medical reported a 38% gross margin in Q4 2025, and Medline's consolidated gross margin was 26.4% in 2025 — 24.3% adjusted EBITDA margin in branded products against 5.5% in distribution.[2][3] Even a scaled contact-lens franchise earns a segment operating margin nearer 27% (CooperVision: $730M on $2.74B) while spending ~$323M of capex.[5] Mixing these tiers into a single "medtech margin" is the fastest way to misprice the level.
• The buyer holds price. Price is capped by concentrated buyers: Group Purchasing Organizations (GPOs) and consolidating hospitals in the surgical children (typically extracting 10–18% off list),[3] the Centers for Medicare & Medicaid Services (CMS) reimbursement schedules (DRG bundles for inpatient surgery, the DMEPOS fee schedule and competitive bidding for prosthetics/orthotics),[3] DSOs and distributors in dental,[4] and vision-insurance plans plus vertically integrated retail chains in optical.[5] Volume, not price, is what actually moves the top line for the strong suppliers: Stryker's 2025 constant-currency organic growth was 9.9% volume and only 0.4% price.[2]
• The cash-pay exception (dental & premium optical). Two children break the "non-discretionary" rule: dental implants (~$2,000–$4,500 per tooth), clear aligners (~$1,000–$7,000) and cosmetic work, and premium/designer eyewear and sunglasses, are largely paid out of pocket — which makes those slices track consumer confidence and behave cyclically, unlike surgery.[4][5]
• The labor exception (dental labs). In 339116, the model is not razor-and-blades but a per-unit job shop: revenue is units × price, labor is the largest cost (payroll runs on the order of a third of receipts), and the margin levers are throughput per technician, remake rate, case mix, offshoring arbitrage, and account concentration.[6] A worsening technician shortage is inflating its single biggest cost, while digital capex raises fixed costs in exchange for throughput.[6]
• Customer concentration cuts both ways. The tiers beneath and beside the brands carry real single-customer risk: contract manufacturer Integer Holdings disclosed that Abbott, Boston Scientific and Medtronic together were 49% of its 2025 sales, and Henry Schein alone was 13% of Dentsply Sirona's 2025 sales.[2][4] In dental labs, winning a DSO contract delivers volume at squeezed prices — and the risk the DSO later insources the work.[6]
• The shared constraint: capacity, inputs, and skilled labor. As manufacturers, all five live on keeping skilled capacity full and on input costs — surgical steel and specialty alloys, medical-grade polymers and silicone, titanium, cobalt-chrome and tantalum, zirconia, resins and precious-metal dental alloys — many of them imported, some from sole or limited suppliers where a switch requires regulatory revalidation, and now tariff-exposed.[2][3][4][5][6]

6. What drives demand

The children share most of their demand drivers, which is why the level moves together over long horizons:

• Aging and chronic disease (the master driver). The U.S. population aged 65 and older rose 9.4% between 2020 and 2023 to roughly 59.2 million, and the Census Bureau projects that adults 65+ will outnumber children under 18 beginning in 2029.[2][3] An older, heavier population drives surgical volume, joint replacement and spine, chronic wounds and amputations, dental restoration and implants, and stronger prescriptions — about 128 million U.S. adults already have presbyopia.[3][4][5] Procedure and case volume is the ultimate unit of demand.
• Technology adoption within each child. Minimally invasive and robotic surgery (which consumes more single-use instruments per case), 3D-printed and patient-specific implants, the analog-to-digital transition in dentistry (scanners at $20,000–$50,000, CAD/CAM mills, chairside printing), and premiumization in lenses (multifocals, myopia-control) all expand the addressable pool and lift value per procedure.[2][3][4][5]
• Site-of-care and buyer-structure shifts. Procedures migrating to lower-cost Ambulatory Surgery Centers (CMS broadened ASC covered-procedure criteria for 2026), and purchasing concentrating into GPOs and DSOs, reshape who buys and at what price.[3][4] DSOs have gone from about 100 in 2010 to over 2,000, roughly 30%+ of U.S. dentists are DSO-affiliated, and the skew is generational — 27% of dentists fewer than ten years out of school versus 9% of those more than 25 years out.[4][6]
• Reimbursement and affordability gate the profitable volume. Coverage decisions and fee schedules can accelerate or stall adoption regardless of clinical merit — and in the cash-pay slices (dental, premium optical), consumer confidence is the gate. Traditional Medicare covers only one pair of eyeglasses or contacts after cataract surgery and no routine replacement eyewear; only 45% of the U.S. population saw a dentist in 2022, and just 40% of working-age adults.[3][4][5][6]
• Access and staffing constrain the volume that demand can convert into. This is a genuinely level-wide brake, not a dental curiosity: HRSA counted 70.6 million people in designated dental shortage areas as of March 2026, and ADA reported in April 2026 that only 60% of dentists considered hygienist staffing adequate while 91% recruiting hygienists found it extremely challenging.[4] Fewer staffed chairs — or fewer cleanroom and lab technicians — cap procedure and consumable volumes regardless of underlying need.[2][6]
• Distinctive drivers worth isolating. The myopia epidemic (roughly 40%+ of the U.S. population is myopic, and rising in children) is a growth engine unique to ophthalmic and now has products behind it — CooperVision's MiSight and, since 2025, FDA-authorized Essilor Stellest spectacle lenses;[5] adult aesthetics drives clear aligners (adults are ~65% of that market);[4] single-use-device reprocessing is a substitute that can reduce new-unit demand in surgical supplies;[3] and GLP-1 weight-loss drugs remain a genuine two-way wildcard for orthopedics (they may reduce obesity-driven joint disease over time while improving patients' fitness for surgery near-term).[3]

7. Regulation

One regulator ties the level together: nearly everything here is an FDA-regulated medical device (dental products under 21 CFR Part 872, contact lenses, and even ordinary spectacles and sunglasses), risk-classified I, II, or III, which sets the market-entry pathway.[2][4][5]

• Class I (low risk — basic instruments, most hand tools, spectacle frames): general controls, often exempt from premarket review — though exempt makers still owe establishment registration, device listing, quality-system, labeling and (for eyewear) impact-resistance compliance, and imports can be detained for failures.[4][5]
• Class II (moderate risk — most surgical instruments, catheters, orthopedic and dental products, clear aligners, most contact lenses): cleared via a 510(k) premarket notification demonstrating "substantial equivalence" to a marketed predicate device, usually without a fresh clinical trial; FDA's FY2025 goal is a decision in roughly 90 days for a well-prepared submission, with the De Novo route for novel low-to-moderate-risk devices lacking a predicate. This is the workhorse pathway for the level and the reason niche entrants can reach market.[2][3][4]
• Class III (high risk — some implants, extended-wear and orthokeratology lenses): full Premarket Approval (PMA), requiring clinical evidence, running years and tens of millions of dollars.[2][3][5] Note the terminology trap the children flag: "FDA cleared" (510(k)) is not "FDA approved" (PMA).[2]

Level-wide regulatory currents to watch:

• Quality-system overhaul, now in force. Effective February 2, 2026, the FDA replaced its Quality System Regulation with the Quality Management System Regulation (QMSR), incorporating the international standard ISO 13485:2016 — harmonizing U.S. rules globally but expanding what inspectors may review (management reviews, supplier and internal audits) and raising transition and compliance cost for every covered manufacturer in the level.[2][3][4][6]
• Sterilization is the level's newest live constraint — and it was absent from the previous version of this page. FDA estimates roughly 50% of sterile U.S. medical devices are sterilized with ethylene oxide (EtO), often the only practical method for polymers and complex devices such as catheters.[2] EPA's 2024 rule sought emissions reductions exceeding 90% at nearly 90 commercial sterilization facilities, but EPA proposed repealing it in March 2026 on compliance and medical-supply grounds — leaving both the regulation and sterilizer capacity planning uncertain for the two heavyweight children.[2][3]
• The medical-device excise tax is gone. The Affordable Care Act's 2.3% device excise tax was permanently repealed in December 2019 — not a current cost, but a reminder the sector's tax exposure is politically live.[2][3]
• Tariffs (the live trade issue). Tariff actions raised the cost of imported devices, components, frames, and dental goods across the level; import dependence is high (many "U.S.-made" instruments use 50–80% imported components; most eyewear frames are imported, with Chinese-origin frames, sunglasses and readers facing combined rates around 150%+ and reciprocal tariffs of ~15–20% on the EU, Japan and Vietnam).[2][5] The cost is now quantified rather than asserted: one large maker guided to roughly $400M of 2025 tariff expense, and Medline attributed a 115-basis-point cut to its 2025 gross margin and a $290 million adverse pretax effect to tariffs and related developments.[2][3]
• FDA capacity. Early-2025 federal workforce reductions cut roughly 180 CDRH staff, raising industry concern about review timelines — a risk to watch rather than a settled fact.[2]
• Child-specific regimes. Reimbursement rules bite hardest in implants — CMS bundled-payment models (the Transforming Episode Accountability Model became mandatory in selected regions on January 1, 2026), competitive bidding, and a 2.83% Medicare conversion-factor cut in 2025 with a further efficiency adjustment for 2026;[3] dental faces the mercury-amalgam phase-down under the Minamata Convention and state scrutiny of direct-to-consumer aligners;[4] optical is governed by the FTC Contact Lens Rule on how lenses are sold (prescription release, one-year validity, and an 8-business-hour verification window that enabled online sellers) and by ANSI Z87.1/OSHA for protective eyewear.[5] Exporters across all five also face the EU Medical Device Regulation.
• Correction to the previous version: dental labs are not comfortably exempt. The prior page described many restorations as exempt "custom devices." The revised child says otherwise: FDA's custom-device exemption is limited to no more than 5 units per year of a device type with further conditions, and ordinary crowns, dentures and abutments produced repeatedly to patient measurements generally should not be assumed to qualify; the 21 CFR 807.65(i) registration exemption is narrow and U.S.-only.[6] FDA drew the line in a June 2025 warning letter to Reset Technology, rejecting the argument that patient-specific partial dentures made from cleared materials constituted exempt lab service.[6] Labs making Class II appliances (sleep-apnea and TMJ devices) or importing foreign-fabricated cases must register and comply, and OSHA/CDC hazards (beryllium in alloys, silica from grinding and sandblasting, methyl methacrylate) carry their own compliance cost.[6] State oversight remains a patchwork — Texas and Florida register and inspect labs; only a few states require offshore-fabrication disclosure.[6]

8. Consolidation

Consolidation is the level's default motion — but it takes two different forms in the big versus the small children, and it now runs in both directions.

• In the two heavyweights (instruments, implants): acquire-approved-product-lines M&A. Incumbents buy cleared, revenue-generating portfolios rather than build from scratch, because FDA clearance, surgeon training, and hospital relationships are the scarce assets. Recent examples span both children — Globus Medical–NuVasive (~$3.1B, closed September 2023), Zimmer Biomet–Paragon 28 (~$1.2B, closed April 2025), and continued deal flow in the contract-manufacturing tier (Quasar Medical's purchase of Nordson's contract-manufacturing operations).[2][3] Within any niche the "competitive" aggregate hides an oligopoly: the top four hold roughly 80%+ of U.S. knee and hip implants and close to 80% of spine (Medtronic ~32%, Globus ~23%), and the top five in advanced wound care hold ~45–50%.[3]
• De-merger is now part of the same story. Johnson & Johnson has said it will spin off its DePuy Synthes orthopaedics business (a unit of roughly $9.2B), and Solventum itself exists because 3M spun it out.[3][4] The giants break themselves apart as readily as they bolt things on — a nuance the previous version of this page missed.
• In the small children: fragmented roll-ups and take-privates. Dental and optical consolidation runs more through financial buyers assembling fragmented bases — DSO roll-ups, distributor take-privates (Patterson → Patient Square, ~$4.1B, closed April 2025), manufacturer buyouts (ZimVie → ArchiMed, ~$730M), and dental-lab networks (Cerberus/National Dentex, 55+ labs).[4][6] Contact lenses are a global "Big Four" oligopoly — Johnson & Johnson (Acuvue), Alcon, CooperVision and Bausch + Lomb — and EssilorLuxottica is a vertically integrated colossus spanning lenses, frames, retail and vision insurance.[5] Not every deal lands: Alcon's agreed takeover of STAAR Surgical was rejected by shareholders and terminated in January 2026.[5]
• New listings run against the tide too. Medline's December 2025 IPO added the largest U.S. medical-surgical consumables platform to public markets, and the previous decade's dental consolidation produced Envista out of Danaher.[3][4] Meanwhile Patterson's exit removed a listed distributor.[4]
• The level's HHI understates all of this. As the ladder in Section 3 shows, an HHI of 164 reflects five industries bundled, not one open market.[1] The moats that actually protect incumbents — clinician switching costs, consignment inventory and sales-rep relationships, robotics ecosystems that lock in consumable pull-through, closed digital-workflow software, and validated supplier qualifications — are real and rising within each child.[2][3][4][6]

9. Risks

The children share a common risk stack, with a few child-specific tails:

• Pricing power sits with the buyer (level-wide). GPOs and hospital consolidation, CMS reimbursement cuts and bundled payments, DSO and distributor leverage, and vision-plan/retail integration all cap price — the most persistent downside in every child.[3][4][5]
• Tariffs and import dependence (level-wide, and now quantified). Concentrated overseas sourcing exposes inputs and finished goods; per-device cost impacts of $2,000–$8,000 on complex devices, ~150%+ combined tariff rates on some Chinese optical goods, Medline's $290M pretax hit, and a ~$400M 2025 tariff guide at one large maker mark the range.[2][3][5]
• Sterilization bottleneck (new to this page). With roughly half of sterile devices dependent on ethylene oxide and EPA's 2024 rule proposed for repeal in 2026, capacity constraints, facility closures, or hurried transfers to alternative sterilizers can interrupt supply and force regulatory supplements — a risk concentrated in 339112/339113 but capable of stopping shipments outright.[2][3]
• Regulatory, recall, and liability risk. Class II devices (the heart of the level) carry the bulk of recalls; implanted and invasive products expose makers to long-tail litigation (metal-on-metal hips, surgical mesh, breast implants); the QMSR transition raises compliance cost; and dental labs face material-safety and disclosure exposure on offshore work, with FDA's 2025 Reset Technology letter showing that "custom" is not a blanket shield.[2][3][6]
• Demand is not a smooth line, even where it trends up. The cash-pay dental and premium-optical slices soften in downturns; elective surgical volume is deferrable (as COVID-19 showed); surgical appliances' real output fell ~8.2% from 2022 to 2023; and U.S. optical volumes and eye exams declined in 2025.[3][4][5] "Healthcare demand always rises" is an inadequate forecasting rule at this level.
• Concentration risk in the supplier and channel tiers. CDMOs trade commercial risk for customer concentration (Integer: three customers, 49% of 2025 sales); manufacturers depend on consolidated distributors (Henry Schein, 13% of Dentsply's 2025 sales); labs depend on DSO contracts that can be insourced; and sole-source inputs and sterilization services appear in the giants' own risk disclosures.[2][3][4][6]
• Technology disruption — sharpest in dental labs. Robotics and new single-use platforms can obsolete an incumbent instrument line, and refractive surgery, IOLs and emerging pharmaceuticals are a long-run (if double-edged) substitute for lenses.[2][5] The clearest structural threat remains disintermediation of dental labs as chairside milling/printing and offshore fabrication shrink the outsourced pie — BLS projects lab-technician employment falling 4.7% from 35,200 in 2024 to 33,600 in 2034, citing 3D printing and other labor-saving technology.[6]
• Skilled-labor scarcity. A genuine shortage of cleanroom technicians (and, acutely, dental-lab technicians, whose training programs are closing as the workforce ages) constrains capacity, complicates reshoring, and inflates the level's biggest cost.[2][6]

10. How to invest & outlook

Match the route to the child.

• Public-market investors get the cleanest access to the two big children. For breadth, the medical-device ETFs (IHI, 0.38%; XHE, 0.35%) hold the instrument and implant names together (plus the excluded electromedical codes) — a diversified "medtech" position.[2] For focus, the listed plays in Section 4 span mega-cap diversified medtech down to focused instrument, implant, dental (ALGN, XRAY, NVST) and contact-lens (COO) specialists, with Medline (MDLN) newly available as consumables exposure since December 2025.[3] Underwrite the relevant product franchise rather than consolidated revenue — Medtronic's Medical Surgical segment was $8.4B in fiscal 2025 but includes activity outside this level, and roughly half of Medline's sales are distribution.[2][3] Reserve valuation, yield, and multiple judgments for a security-specific screen — and note that income is thin in the dental names.[4]
• Private-market investors get disproportionate access to the three small children and the supplier tiers: contract manufacturers/CDMOs feeding the surgical children (a ~$89B, fast-growing, PE-favored segment),[2] orthopedic/prosthetics and dental-lab roll-ups,[3][6] DSO and optical-lab platforms,[4][5] and venture-stage surgical robotics and single-use-device startups the giants ultimately buy. The diligence questions the children converge on are consistent across the level: recurring/consumable mix and installed-base pull-through, FDA pathway and inspection history, recall exposure, customer concentration, sole-source inputs and sterilization dependence, validated capacity, equipment age and utilization, and — in the craft trades — technician retention, remake rates, and domestic/offshore mix.[2][5][6] These offer the same demographic tailwinds without the branded-incumbent premium, at the cost of liquidity and single-asset regulatory risk.

Outlook (forward-looking judgment). The structural case for the level is durable and demographically anchored: aging, chronic disease, the shift to minimally invasive/robotic surgery, digital dentistry, and the myopia epidemic should keep unit volumes and recurring revenue growing at a mid-single-digit pace through the back half of the decade, with faster niches (clear aligners ~15%/yr, dental implants ~8.5%/yr, advanced wound care mid-to-high single digits, myopia management) running higher.[2][3][4][5] Four of the five children participate; the honest exception is dental labs, where digital and offshore disintermediation make the domestic pie flat-to-shrinking even as the strongest labs industrialize and take share.[6]

Two caveats belong alongside that case. First, the long-run demand curve and the year-to-year output series are not the same thing — the revised children show a real output decline in surgical appliances (2022→2023) and falling optical volumes in 2025 sitting inside an otherwise rising trend.[3][5] Second, the near-term swing factors across the level are policy and cost, not demand: how far tariffs and supply-chain re-regionalization compress margins,[2][3][5] whether FDA review capacity and the QMSR transition hold up,[2][3] whether ethylene-oxide sterilization capacity stays available while EPA reconsiders its 2024 rule,[2][3] and how hard consolidated buyers (GPOs, CMS, DSOs, vision plans) squeeze price.[3][4] For patient investors the appeal is what it has always been — largely non-cyclical demand, high gross margins in the branded tiers, recurring-consumable economics, and steady consolidation — now with the caveat that this is a policy- and trade-exposed manufacturing level, not a purely defensive one, that its margin profile spans branded 50–67% and distribution/contract 26–38%, and that the two large children carry the investable weight while the three small ones carry most of the private-market intrigue.

---

Sources

1. U.S. Census Bureau. 2022 Economic Census (receipts, firms, CR4/CR8/CR20/CR50, HHI) and County Business Patterns 2023 (establishments, employment, annual payroll) — NAICS 33911 and its children 339112/339113/339114/339115/339116. Our ingested federal ground-truth statistics for this level, cross-checked against each child primer's own Census figures. 2022–2023. https://www.census.gov/programs-surveys/economic-census.html
2. Histometrics child primer — Surgical and Medical Instrument Manufacturing (NAICS 339112), synthesizing U.S. Census (2022 EC / 2023 CBP; CR4 ~26%, HHI 271), FDA device-classification, 510(k)/De Novo/PMA and QMSR guidance, FDA and EPA ethylene-oxide sterilization materials (2024 rule and 2026 proposed repeal), Precedence Research / Grand View / SelectUSA on the U.S. device market (~$191B; U.S. ~46% of global sales), Stryker, Intuitive Surgical, BD, Boston Scientific, Teleflex, ICU Medical, Integra, CONMED, Merit Medical, Integer and Medtronic filings, tariff analyses (Everstream / Baker McKenzie), IHI and XHE fund documents, and 2025 M&A / CDMO market (~$89B) reporting.
3. Histometrics child primer — Surgical Appliance and Supplies Manufacturing (NAICS 339113), synthesizing U.S. Census (2022 EC / 2023 CBP; CR4 35.1%, HHI 417.7) and BLS sectoral-output and employment series (real output −8.2% 2022→2023), CMS reimbursement (DRG, DMEPOS, competitive bidding, CJR/TEAM mandatory Jan 1 2026), FDA device-regulation, QMSR (effective Feb 2, 2026), 3D-printing and single-use reprocessing guidance, EPA ethylene-oxide reconsideration, orthopedic and advanced-wound-care market research (U.S. orthopedics ~$33.4B; AWC top-5 ~45–50%), GPO savings data, Medline's 2025 Form 10-K (IPO Dec 2025; $28.4B sales; 26.4% gross margin; $290M tariff impact), Stryker and Globus filings, J&J's planned DePuy Synthes spin-off, and 2023–2025 orthopedic M&A (Globus–NuVasive, Zimmer–Paragon 28, ZimVie spine–H.I.G. $375M).
4. Histometrics child primer — Dental Equipment and Supplies Manufacturing (NAICS 339114), synthesizing U.S. Census (2022 EC / 2023 CBP; CR4 ~45%, HHI ~665), Align / Dentsply Sirona / Envista / Solventum / Straumann filings, FDA 21 CFR Part 872, device-exemption and QMSR guidance, CMS National Health Expenditures (U.S. dental services $189.2B in 2024), dental-implant and clear-aligner market research, CDC oral-health surveillance, ADA Health Policy Institute DSO-affiliation and hygienist-shortage data, HRSA dental shortage-area statistics, iData tariff analysis, and 2024–2025 take-privates (ZimVie→ArchiMed ~$730M, Patterson→Patient Square ~$4.1B).
5. Histometrics child primer — Ophthalmic Goods Manufacturing (NAICS 339115), synthesizing U.S. Census (2022 EC / 2023 CBP; CR4 59.3%, CR8 73.3%, HHI suppressed) and the NAICS boundary that places intraocular lenses in 339113 and ophthalmic surgical instruments in 339112, Cooper / Bausch + Lomb / Alcon / EssilorLuxottica / Warby Parker filings, FDA contact-lens and spectacle/sunglass device requirements, the FTC Contact Lens Rule, OSHA 1910.133 and ANSI Z87.1, CDC and NEI epidemiology (45M contact-lens wearers; ~128M with presbyopia), The Vision Council's 2025 U.S. optical-industry estimate ($69.5B; 94% eyewear usage; volume vs. price dynamics) and tariff updates, and the terminated Alcon–STAAR transaction (January 2026).
6. Histometrics child primer — Dental Laboratories (NAICS 339116), synthesizing U.S. Census (2022 EC / 2023 CBP; CR4 24.1%, CR50 46.3%, HHI 173.1), CMS National Health Expenditures (U.S. dental services ~$189B, 2024), BLS occupational wage data (mean ~$52,400, May 2024) and employment projections (35,200 in 2024 → 33,600 in 2034), FDA dental-device, CAD/CAM, 21 CFR 807.65(i), custom-device-exemption and QMSR guidance plus the June 2025 Reset Technology warning letter, OSHA/CDC occupational-hazard materials, Texas and Florida state lab-registration rules, digital-dentistry and offshoring/disintermediation reporting, ADA utilization and DSO-affiliation data, Modern Dental Group's 2024 annual report, and PE roll-up activity (Cerberus/National Dentex, Glidewell).